TY - JOUR
T1 - Should the risk for uterine cancer influence decision making for prophylactic hysterectomy in BRCA1/2 mutated patients- a systematic review and meta-analysis
AU - Nahshon, Chen
AU - Segev, Yakir
AU - Gemer, Ofer
AU - Bar Noy, Tomer
AU - Schmidt, Meirav
AU - Ostrovsky, Ludmila
AU - Lavie, Ofer
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/3/1
Y1 - 2021/3/1
N2 - Objective: To study the possible association between uterine cancer and the BRCA1/2 associated cancer syndrome and discuss the implications of such an association on the clinical managment of patients with BRCA1/2 mutations. Methods: A systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement. Study protocol was prospectively registered at PROSPERO International prospective register of systematic reviews (registration number CRD42020193496). Considered for inclusion were studies providing the diagnosis rate of uterine cancer in patients with BRCA1/2 mutations by comparing observed and expected rate according to a known disease incidence. The results were measured by standardized incidence ratio (SIR). The primary outcome was defined as any uterine cancer diagnosis and subgroup analyses were conducted for uterine serous papillary cancer (USPC) specifically and for BRCA1 and BRCA2 mutations separately. Results: 4591 records were identified through database search; eight studies were finally included, comprising 13,098 patients with BRCA1/2 mutations. BRCA1/2 mutated patients were found to have a significantly higher risk for uterine cancer compared to the general population (SIR = 2.22, 95% CI 1.76–2.8, p < 0.001). A higher incidence of USPC was also found in patients with BRCA1/2 mutations (SIR = 17.97, 95% CI 9.89–32.66, p < 0.001), as well as in a separate analysis for BRCA1 (SIR = 2.81, 95% CI 2.09–3.79, p < 0.001) and BRCA2 (SIR = 1.75, 95% CI 1.09–2.80, p < 0.001) mutations. Conclusion: Patients who carry a BRCA1/2 mutation are at a significantly higher risk of developing uterine cancer, specifically USPC, supporting that USPC may be a component of the BRCA1/2 syndrome. The decision to perform concurrent hysterectomy at the time of the risk reduction bilateral salpingo –oophorectomy surgery should be considered individually.
AB - Objective: To study the possible association between uterine cancer and the BRCA1/2 associated cancer syndrome and discuss the implications of such an association on the clinical managment of patients with BRCA1/2 mutations. Methods: A systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses statement. Study protocol was prospectively registered at PROSPERO International prospective register of systematic reviews (registration number CRD42020193496). Considered for inclusion were studies providing the diagnosis rate of uterine cancer in patients with BRCA1/2 mutations by comparing observed and expected rate according to a known disease incidence. The results were measured by standardized incidence ratio (SIR). The primary outcome was defined as any uterine cancer diagnosis and subgroup analyses were conducted for uterine serous papillary cancer (USPC) specifically and for BRCA1 and BRCA2 mutations separately. Results: 4591 records were identified through database search; eight studies were finally included, comprising 13,098 patients with BRCA1/2 mutations. BRCA1/2 mutated patients were found to have a significantly higher risk for uterine cancer compared to the general population (SIR = 2.22, 95% CI 1.76–2.8, p < 0.001). A higher incidence of USPC was also found in patients with BRCA1/2 mutations (SIR = 17.97, 95% CI 9.89–32.66, p < 0.001), as well as in a separate analysis for BRCA1 (SIR = 2.81, 95% CI 2.09–3.79, p < 0.001) and BRCA2 (SIR = 1.75, 95% CI 1.09–2.80, p < 0.001) mutations. Conclusion: Patients who carry a BRCA1/2 mutation are at a significantly higher risk of developing uterine cancer, specifically USPC, supporting that USPC may be a component of the BRCA1/2 syndrome. The decision to perform concurrent hysterectomy at the time of the risk reduction bilateral salpingo –oophorectomy surgery should be considered individually.
KW - BRCA mutation
KW - Endometrial cancer
KW - Hereditary cancer
KW - Prophylactic hysterectomy
KW - Uterine cancer
UR - http://www.scopus.com/inward/record.url?scp=85097752370&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2020.11.034
DO - 10.1016/j.ygyno.2020.11.034
M3 - Review article
C2 - 33309051
AN - SCOPUS:85097752370
SN - 0090-8258
VL - 160
SP - 755
EP - 762
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 3
ER -